Nitroxoline revisited: antibacterial mechanisms, spectrum, and therapeutic potential of an old drug in the era of antimicrobial resistance
Biochemical Society Transactions · 29.07.2026 · 54 (7) · 937-947
DOI: 10.1042/bst20250045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 09.07.2026. Verfasst von Elisabetta Cacace und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Institute of Microbiology and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Nitroquinolines, Anti-Bacterial Agents, Drug Resistance, Microbial. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Stiftung für Medizinisch-Biologische Forschung (Novartis Foundation for Medical-Biological Research), Dr. Rolf M. Schwiete Stiftung (Dr. Rolf M. Schwiete Foundation).
Abstract (Originalsprache)
As the spread of antimicrobial resistance outpaces antibiotic discovery and marketing, there is a critical need to revisit approved compounds with untapped potential. Metal-based complexes (metallo-antimicrobials) represent ideal candidates for such efforts due to their pleiotropic effects, which, unlike antibiotics with single protein targets, may have lower resistance potential. With its well-characterised safety profile, nitroxoline, an 8-hydroxyquinoline derivative, is a prominent compound of this kind. Here, we review recent advances in our understanding of nitroxoline’s multimodal mode of action, focusing on its disruption of metal homeostasis at the intracellular and extracellular level. We further explore its clinical utility, including its low propensity for resistance development, and its potential for both combinatorial therapy and as an anti-biofilm agent. Although beyond the scope of the present review, we refer to nitroxoline’s antifungal effects whenever they represent a relevant comparison with its antibacterial activity. We highlight current knowledge gaps in nitroxoline’s mechanism and in vivo activity that should be bridged to accelerate its repurposing, particularly in the treatment of multidrug-resistant and biofilm-associated infections. Several recent reviews have examined nitroxoline from chemical, clinical, and repurposing perspectives [1, 2, 3, 4]. The present work complements these by providing a mechanistic synthesis of nitroxoline’s effects in bacteria, linking its multimodal mode of action to the knowledge gaps that should be addressed before clinical repurposing can proceed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Institute of Microbiology and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland.
- Institute for Medical Microbiology and Infection Control, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
- University Center for Infectious Diseases (UCI), University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
ORCID-Profile: Elisabetta Cacace, Stephan Göttig
Förderung
- Novartis Stiftung für Medizinisch-Biologische Forschung (Novartis Foundation for Medical-Biological Research)
- Dr. Rolf M. Schwiete Stiftung (Dr. Rolf M. Schwiete Foundation)
Zitieren
APA
Cacace, E., & Göttig, S. (2026). Nitroxoline revisited: antibacterial mechanisms, spectrum, and therapeutic potential of an old drug in the era of antimicrobial resistance. Biochemical Society Transactions, 54(7), 937-947. https://doi.org/10.1042/bst20250045
Vancouver
Cacace E, Göttig S. Nitroxoline revisited: antibacterial mechanisms, spectrum, and therapeutic potential of an old drug in the era of antimicrobial resistance. Biochemical Society Transactions. 2026;54(7):937-947. doi:10.1042/bst20250045
BibTeX
@article{Cacace2026,
author = {Cacace, Elisabetta and Göttig, Stephan},
title = {Nitroxoline revisited: antibacterial mechanisms, spectrum, and therapeutic potential of an old drug in the era of antimicrobial resistance},
journal = {Biochemical Society Transactions},
year = {2026},
volume = {54},
number = {7},
pages = {937--947},
doi = {10.1042/bst20250045}
}
EUVIMED